Top 10 Developments in Lupus Nephritis

被引：5

作者：

Chen, Teresa K. ^{[1
]}

Fine, Derek M. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD 21205 USA

来源：

CURRENT RHEUMATOLOGY REPORTS | 2013年 / 15卷 / 09期

关键词：

Lupus nephritis; Kidney; Proliferative lupus nephritis; Membranous lupus nephritis; Renal transplantation; APOL1; Induction therapy; Maintenance therapy; Systemic lupus erythematosus; SLE; Mycophenolatemofetil; Rituximab; Treatment; Multitargeted therapy; Epidemiology; B-LYMPHOCYTE STIMULATOR; STAGE RENAL-DISEASE; MYCOPHENOLATE-MOFETIL; CONTROLLED-TRIAL; DOUBLE-BLIND; COLLAPSING GLOMERULOPATHY; MEMBRANOUS NEPHROPATHY; CLINICAL-TRIALS; ERYTHEMATOSUS; THERAPY;

D O I：

10.1007/s11926-013-0358-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

引用

页数：7

共 50 条

[31] Pediatric lupus nephritis: more options, more chances?
Vachvanichsanong, P.
McNeil, E.
LUPUS, 2013, 22 (06) : 545 - 553
[32] Do we really need cyclophosphamide for lupus nephritis?
Wenderfer, Scott E.
Cooper, Jennifer C.
PEDIATRIC NEPHROLOGY, 2024, 39 (11) : 3193 - 3200
[33] Lupus nephritis - An update on disparities affecting african americans
Portalatin, Gilda M.
Gebreselassie, Surafel K.
Bobart, Shane A.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2022, 114 (03) : S34 - S42
[34] Rituximab as Treatment for Lupus Nephritis
Pimentel-Quiroz, Victor R.
Reategui-Sokolova, Cristina
Gamboa-Cardenas, Rocio V.
Elera-Fitzcarrald, Claudia
Rodriguez-Bellido, Zoila
Pastor-Asurza, Cesar A.
Perich-Campos, Risto
Alarcon, Graciela S.
Ugarte-Gil, Manuel F.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (06) : 235 - 238
[35] Synthetic pharmacotherapy for lupus nephritis
Moroni, G.
Ponticelli, C.
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (02) : 175 - 186
[36] Corticosteroids in Lupus Nephritis and Central Nervous System Lupus
Kamen, Diane L.
Zollars, Eric S.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (01) : 63 - +
[37] Belimumab for systemic lupus erythematosus - Focus on lupus nephritis
Pluess, Marlene
Piantoni, Silvia
Tampe, Bjoern
Kim, Alfred H. J.
Korsten, Peter
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
[38] Lupus nephritis
Melderis, S.
Wiech, T.
Iking-Konert, C.
Steinmetz, O. M.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (07): : 593 - 608
[39] Lupus Nephritis
Wenderfer, Scott E.
Eldin, Karen W.
PEDIATRIC CLINICS OF NORTH AMERICA, 2019, 66 (01) : 87 - +
[40] Transplant outcomes in kidney recipients with lupus nephritis, and systematic review
Kim, J. E.
Kim, Y. C.
Min, S-l
Lee, H.
Ha, J.
Chin, H. J.
Kim, Y. S.
Han, S. S.
LUPUS, 2020, 29 (03) : 248 - 255

← 1 2 3 4 5 →